Dear Editor,

Both arterial and venous thrombotic complications have been reported in patients affected by COVID-19, especially in those critically ill. An emerging body of evidence is supporting our understanding of a *so-called* Coronavirus-associated coagulopathy (CAC) \[[@CR1]\]. From a clinical point of view, in the initial phase of the pandemic, numerous empirical therapeutic strategies have been used, to include the use of heparins (alone or in association), hydroxychloroquine, steroids, immunomodulators, as well as plasma from convalescent patients from COVID-19 \[[@CR2], [@CR3]\]. However, data are still limited as these approaches have been reported most of the time in non-controlled studies. Nevertheless, regardless the intrinsic limitations of the available studies, some promising results in improving the clinical outcome, to include the thrombotic complications, have been reported. From a laboratory perspective, few considerations are similarly needed. While aPTT is often prolonged in these patients, it does not seem to be associated with a bleeding tendency but rather to the presence of antiphospholipid antibodies, mainly the lupus anticoagulant \[[@CR4], [@CR5]\]. Similarly, albeit modest and inconstant thrombocytopenia, increased (sometimes dramatically high) levels of D-dimer, and slightly prolonged prothrombin time (PT) are commonly observed, the mechanisms supporting the developed of CAC are still elusive \[[@CR1]\]. The International Society of Thrombosis and Haemostasis (ISTH) recently published an "interim guidance" aiming to define some characteristics of the CAC \[[@CR6]\]. Among others, the ISTH interim guidance highlighted some frequently observed hemostatic alterations in patients with CAC, to include D-dimer usually increased, prothrombin time usually only marginally deranged and platelets count usually within rage or slightly reduced. Those observation are in line with the preliminary observations at the beginning of the pandemic outbreak \[[@CR6]--[@CR8]\]. Critically, the mentioned hemostatic alternations differ from those usually observed during the disseminated intravascular coagulopathy \[[@CR9], [@CR10]\]. While discriminating between a consumption coagulopathy vs. a thrombotic microangiopathy might be challenging, the differentiation is crucial for therapeutic purpose.

In order to further investigate the CAC, we tested ADAMTS-13 and von Willebrand factor (vWF) plasma levels in 88 consecutive PCR-proven COVID-19 admitted patients (main characteristics detailed in Table [1](#Tab1){ref-type="table"}). Adamts13 activity and von Willebrand antigen (vWF:Ag) measurements were performed using CliA activity assays (HemosIL Acustar ADAMTS13 activity, IL, Lexington, MA, USA). Table 1Laboratory profile at hospital admission dividing patients according to the outcomeNot survivors = 9Survivors = 79*p*Male (*N*, %)666.7%5468.4%0.91Age (years: mean; SD)71.897.159.3712.70.037PLTs (N/µL; mean ± SD)139.6581.4267.9163.090.022vWF (IU/dL, mean; SD)395.52113.21295.5132.760.033ADAMTS-13 (%, mean; SD)32.1715.5650.618.170.035PT/INR (mean; SD)1.220.301.10.110.055D-Dimer (ng/ml; mean ± SD)4198.334947.331494.62024.170.106D-Dimer \> 3000 ng/ml (*N*, %)555.6%7(8.8%)0.0001F/U days (mean; SD)11.67.710.76.950.077*vWF* von Willebrand factor, *PLTs* platelets, *F/U* follow-up

ADAMTS-13 levels were significantly reduced in all COVID-19 patients (CP) when compared to healthy controls (HC) (CP, mean 48.71 ± 18.7%, HC, 108 ± 9.1%; normal value 60--130%). These deranged values are similar to those observed in patients with thrombotic thrombocytopenic purpura (TTP), while ADMTS 13 is not generally reduced during a DIC.

Antibodies direct to ADAMTS 13 (assessed by Bethesda assay) were tested in the 25 patients with lowest ADAMTS 13 levels. Both ADAMTS-13 activity and antibodies anti- ADAMTS-13 were tested on the same sample. No patients were found to have significantly increased levels of anti- ADAMTS-13 antibodies (a borderline level was found in 1/25 patient).

Overall, in our cohort we observed a mortality rate of 10.2% (9/88). Patients who died had significant lower levels of ADAMTS-13 and higher levels of von Willebrand factor (vWF) when compared to patients with non-fatal outcome (Table [1](#Tab1){ref-type="table"}). After survival analysis, ADAMTS-13 plasma levels \< 30% were significantly associated with a higher mortality (Fig. [1](#Fig1){ref-type="fig"}). Interestingly, as previously reported, also elevated levels of D-Dimer were associated with a fatal outcome \[[@CR4], [@CR5]\]. Taken the above together, CAC features seems more in line with a thrombotic, TTP-like microangiopathy (almost normal hemostasis, elevated vWF high and low ADAMTS-13, platelet count slightly reduced) rather than with a DIC (PT and antithrombin levels reduced, reduced fibrinogen, PLTS variably reduced, ADAMTs-13 and vWF not described). These features could be related to the ADAMTS-13 "consumption" due to excess of circulating vWF (thrombotic tendency secondary to a "gain of factor"); the presence of anti-ADAMTS-13 antibodies was excluded in our cohort. In conclusion, high VWF plasma levels associated to low ADAMTS 13 could explain, at least in part, the strong thrombotic tendency in these patients. Our data could have the potential to guide possible new therapeutic options.Fig. 1Kaplan--Meier survival curves in COVID-19 patients according to ADATMS-13 plasma activity
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